BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning...
BC Innovations | Aug 9, 2019
Tools & Techniques

The next frontier for single-cell analysis

With an explosion in scalability, single-cell analysis has begun to invade every aspect of drug development, with early benefits showing themselves in precision targeting. The field’s next challenge is to integrate a wider array of...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BC Innovations | May 4, 2017
Translation in Brief

A window to IBD

An academia-industry collaboration has identified the cytokine oncostatin M (OSM) as possibly the first biomarker for predicting whether a patient with inflammatory bowel disease (IBD) will respond to anti- tumor necrosis factor α (TNFα) therapy....
BC Week In Review | Feb 10, 2017
Company News

J&J, Mistubishi Tanabe Pharma deal

Johnson & Johnson’s Janssen Pharmaceutical K.K. unit granted Mitsubishi co-promotion rights to Stelara ustekinumab to treat Crohn’s disease. The human mAb inhibiting IL-12 and IL-23 is under review for the indication in Japan. The companies...
BC Week In Review | Dec 30, 2016
Clinical News

Simponi Aria regulatory update

Johnson and Johnson’s Janssen Biotech Inc. unit submitted a pair of sBLAs to FDA for Simponi Aria golimumab to treat active psoriatic arthritis and active ankylosing spondylitis, respectively. Simponi Aria is approved in the
BioCentury | Aug 22, 2016
Product Development

Interception inception

The first clinical trial to come from the Janssen Research & Development LLC's Disease Interception Accelerator will move upstream from the way Type I diabetes is treated today, even if it doesn't directly prevent the...
BioCentury | Jun 27, 2016
Product Development

Fishing upstream

Anti-inflammatory biologics have transformed the treatment of autoimmune diseases, but Johnson & Johnson's Janssen Research & Development LLC unit wants to intercept the processes that lead to inflammation in the first place. As early as...
BC Week In Review | Jun 6, 2016
Clinical News

Simponi golimumab regulatory update

EMA’s CHMP recommended expanding the label of Simponi golimumab from Johnson & Johnson to include treatment of polyarticular juvenile idiopathic arthritis (JIA). J&J is seeking approval of the mAb against tumor necrosis factor (TNF) alpha...
BC Week In Review | Feb 8, 2016
Company News

AbbVie, Merck, Pfizer, UCB sales and marketing update

The U.K.’s NICE issued final guidance recommending five compounds that target tumor necrosis factor (TNF) alpha to treat ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults whose disease has responded inadequately to NSAIDs. The drugs...
Items per page:
1 - 10 of 142